Research Topics
| M S SaagSummaryAffiliation: University of Alabama at Birmingham Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?Keri N Althoff
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
AIDS Res Ther 7:45. 2010..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study GroupM S Saag
Department of Medicine, Comprehensive Cancer Center, University of Alabama School of Medicine at Birmingham 35294 2050, USA
Clin Infect Dis 28:291-6. 1999..27-27.14; P = .04). Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease. Flucytosine may contribute to the prevention of relapse if used during the first 2 weeks of primary therapy...
The experts speak. Burn-out among HIV care providers. Interview by Vicki GlaserMichael S Saag
AIDS Clinic and Center for AIDS Research, University of Alabama at Birmingham, USA
AIDS Patient Care STDS 20:385-90. 2006
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virusMichael S Saag
Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL 39294 2050, USA
Clin Infect Dis 42:126-31. 2006....
Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patientsMichael S Saag
AIDS Outpatient Clinic, University of Alabama at Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 20:1037-45. 2004..Hemoglobin increased significantly in all subgroups of race, zidovudine use, CD4+ cell count, and viral load. Once-weekly epoetin alfa was well tolerated. Once-weekly epoetin alfa is effective in improving QOL and Hb measures...
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1Michael Saag
School of Medicine, University of Alabama, Birmingham, AL 35294 2050, USA
J Infect Dis 199:1638-47. 2009..A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in treatment-experienced patients infected with dual- or mixed-tropic HIV-1...
Duration of highly active antiretroviral therapy regimensRay Y Chen
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 35294 2050, USA
Clin Infect Dis 37:714-22. 2003..6 years, and medication toxicity-associated events were the cause of one-half of discontinuations. Only a history of opportunistic infection and injection drug use were significantly associated with shorter regimen duration...
Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patientsM S Saag
University of Alabama at Birmingham 35294 2050, USA
AIDS Res Hum Retroviruses 15:1413-7. 1999..This trial demonstrates that itraconazole oral solution is a useful therapy in the treatment of HIV-infected patients with fluconazole-refractory oropharyngeal candidiasis...
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of AmericaM S Saag
University of Alabama at Birmingham, 35294 2050, USA For the Mycoses Study Group Cryptococcal Subproject
Clin Infect Dis 30:710-8. 2000..In all cases of cryptococcal meningitis, careful attention to the management of intracranial pressure is imperative to assure optimal c..
The impact of highly active antiretroviral therapy on HIV-specific immune functionM S Saag
AIDS Clinical Trials Unit, The University of Alabama at Birmingham, 35294 2050, USA
AIDS 15:S4-10. 2001..The long-term goal is to discontinue HAART and permit the reconstituted immune system to contain whatever small amounts of the virus remain...
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infectionS A Call
Division of General Internal Medicine and Birmingham Veterans Affairs Medical Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA
J Infect Dis 183:401-8. 2001..In this cohort, phenotypic testing results enhanced the ability to predict sustained long-term suppression of virus load...
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)M S Saag
University of Alabama at Birmingham, Alabama 35294-2050, USA
AIDS 15:1971-8. 2001..CONCLUSIONS: Nelfinavir plus ZDV/3TC was superior to ZDV/3TC/placebo. In addition, the 750 mg tid nelfinavir dose was better than the 500 mg tid dose. Virologic responses were sustained over 12 months...
Initiation of antiretroviral therapy: implications of recent findingsMichael S Saag
University of Alabama at Birmingham, Birmingham, Alabama, USA
Top HIV Med 12:83-8. 2004..This article summarizes a presentation on initiation of antiretroviral therapy by Michael S. Saag, MD, at International AIDS Society-UsA course in New York in March 2004...
The therapeutic implications of timely linkage and early retention in HIV careKimberly B Ulett
University of Alabama School of Medicine, Birmingham, Alabama, USA
AIDS Patient Care STDS 23:41-9. 2009..Missed clinic visits represent an important obstacle to the timely initiation of antiretroviral therapy. These data inform development of interventions to improve linkage and retention in HIV care, an emerging area of growing importance...
Antiretroviral prescribing patterns in treatment-naïve patients in the United StatesJames A McKinnell
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
AIDS Patient Care STDS 24:79-85. 2010..In contrast, regimen sequencing beyond the first regimen remained complex. These shifts in ART prescribing patterns may have implications for collaborative HIV care...
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl
Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
J Infect Dis 188:625-34. 2003..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trialMichael S Saag
University of Alabama Research Clinic, Birmingham, USA
JAMA 292:180-9. 2004..005). CONCLUSION: Once-daily emtricitabine appeared to demonstrate greater virological efficacy, durability of response, and tolerability compared with twice-daily stavudine when used with once-daily didanosine and efavirenz...
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapyXiping Wei
Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
Antimicrob Agents Chemother 46:1896-905. 2002..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?Shashwatee Bagchi
Division of Geographic Medicine and Center for AIDS Research, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Clin Infect Dis 44:135-8. 2007..No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy...
Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine careJustin S Routman
Divisions of Infectious Diseases, Department of Medicine, University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
Clin Infect Dis 50:574-84. 2010..Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied...
Short-term discontinuation of HAART regimens more common in vulnerable patient populationsLindsay S Robison
University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 24:1347-55. 2008..S. HIV/AIDS epidemic. More vigilant monitoring of patient populations at higher risk of toxicity and virologic failure may allow for improved HAART regimen durability...
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes studyJames A McKinnell
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
AIDS 23:1539-46. 2009....
Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practiceRay Y Chen
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 18:909-16. 2002..We conclude that the majority of our patients in virologic failure who underwent a temporary TI recovered 90% of their baseline CD4(+) cell counts and returned to within 2-fold of their baseline VL when HAART was resumed...
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapyRuimin Tan
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
J Acquir Immune Defic Syndr 47:553-8. 2008..The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood...
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissuesR P Bucy
Department of Pathology, University of Alabama Birmingham, Birmingham, Alabama 35233 7331, USA
J Clin Invest 103:1391-8. 1999....
Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinicJames H Willig
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, USA
Clin Infect Dis 46:1315-8. 2008..Clinical inertia was observed in 44% of cases. Patients with higher baseline LDL levels were less likely to experience inertia, whereas women and those in the highest coronary heart disease risk category were more likely to be affected...
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
JAMA 296:827-43. 2006..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
Failure to establish HIV care: characterizing the "no show" phenomenonMichael J Mugavero
Division of Infectious Diseases and International Health, Department of Medicine, University of Alabama at Birmingham, USA
Clin Infect Dis 45:127-30. 2007....
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA declineJ Michael Kilby
Division of Infectious Diseases and 1917 HIV Research Clinic, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294 2050, USA
AIDS 22:957-62. 2008..Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen...
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyJames H Willig
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
AIDS 22:1951-60. 2008..Modern regimens are thought to possess greater tolerability and convenience. We hypothesized this would translate into greater durability...
Missed visits and mortality among patients establishing initial outpatient HIV treatmentMichael J Mugavero
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, 908 20th St South, Birmingham, AL 35294 2050, USA
Clin Infect Dis 48:248-56. 2009....
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, ZambiaBenjamin H Chi
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
Int J Epidemiol 38:746-56. 2009..In resource-constrained settings, however, there are few validated measures. We examined the correlation between clinical outcomes and the medication possession ratio (MPR), a pharmacy-based measure of adherence...
Racial disparities in HIV virologic failure: do missed visits matter?Michael J Mugavero
Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
J Acquir Immune Defic Syndr 50:100-8. 2009..Racial/ethnic health care disparities are well described in people living with HIV/AIDS, although the processes underlying observed disparities are not well elucidated...
Gender differences in discontinuation of antiretroviral treatment regimensMirjam Colette Kempf
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
J Acquir Immune Defic Syndr 52:336-41. 2009..Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender...
Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosingJames H Willig
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL, USA
J Acquir Immune Defic Syndr 53:215-21. 2010..Whereas access to antiretroviral therapy (ART) for HIV-infected individuals in the developing world is increasing, data on factors impacting initial regimen durability are lacking...
Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinicJames L Raper
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 2050, USA
Clin Infect Dis 51:718-24. 2010..60 per PA. Although evidence supports that PA reduces third-party expenditures, it significantly delays medication accessibility for patients and imposes high costs that negatively impact operating margins for health care providers...
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeksJames H Willig
Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
AIDS Res Hum Retroviruses 26:1279-85. 2010..New agents have transformed the treatment landscape for ARV-experienced patients, with effectiveness in routine clinical care mirroring efficacy in clinical trials...
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomesJeffrey S A Stringer
Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
JAMA 296:782-93. 2006..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record eraJames H Willig
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, USA
Clin Infect Dis 45:658-61. 2007..Understanding the factors related to nucleoside reverse-transcriptase inhibitor dosing errors is an important step in the building of preventive tools...
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby
UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294 2050, USA
AIDS Res Hum Retroviruses 18:685-93. 2002..Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment...
Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing careLaura H Bachmann
Department of Medicine, The University of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, USA
Sex Transm Dis 32:20-6. 2005..Determination of the prevalence and factors associated with risk-taking behaviors among HIV clinic attendees is needed...
Sustained HIV viral suppression following treatment interruption: an observational studyRoger Bedimo
University of Alabama, Birmingham, Alabama 85294, USA
AIDS Res Hum Retroviruses 22:40-4. 2006..Examining the immune responses of nonrebounders may contribute to the understanding of protective immunity to HIV...
Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIVB J Feldman
Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA 98104, USA
AIDS Behav 17:307-18. 2013..These results and the SRSI's low patient burden suggest its routine use could be helpful for assessing adherence in clinical care and should be more widespread, particularly where more complex instruments may be impractical...
Gastrointestinal complications of HIV infection: changing priorities in the HAART eraC M Wilcox
Department of Medicine, Division of Gastroenterology and Hepatology, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294 0007, USA
Gut 57:861-70. 2008....
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical SystemsMari M Kitahata
Department of Medicine, University of Washington, Seattle, 98195, USA
Int J Epidemiol 37:948-55. 2008
EnfuvirtideRay Y Chen
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 908 20th Street South, CCB #142, Birmingham, Alabama 35294-2050, USA
Expert Opin Investig Drugs 11:1837-43. 2002..Based on these studies, enfuvirtide will likely play a significant role in the treatment of patients with limited treatment options...
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002Roger Bedimo
University of Alabama at Birmingham, USA
Clin Infect Dis 39:1380-4. 2004..87; P<.0002). The mean CD4 cell count was lower among patients with ADMs than among those with non-ADMs. A longer duration of survival during highly active antiretroviral therapy might explain the increasing incidence of non-ADMs...
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]James A McKinnell
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
Curr Opin HIV AIDS 4:513-7. 2009..To provide an update on viral entry inhibitors focusing on recently published clinical trials, the routine clinical use of these medications, and future drug candidates...
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionBrandon F Keele
Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
Proc Natl Acad Sci U S A 105:7552-7. 2008....
Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 casesM E Coghlan
Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA
Clin Infect Dis 33:1914-21. 2001..The increasing number of cases identified during the study period suggests that physicians better recognize symptomatic lactic acidosis and/or that cumulative NRTI exposure may increase the risk for this syndrome...
Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapyC E O'Sullivan
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham AL 39294 0006, USA
J Infect Dis 180:847-9. 1999..1 to 1.7 at 385 days with a commensurate rise in median CD4 T cells to 166/mm3. Immune reconstitution secondary to HAART results in a significant and progressive decline in CMV viremia in the absence of specific anti-CMV therapy...
Distribution of health care expenditures for HIV-infected patientsRay Y Chen
Department of Internal Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Clin Infect Dis 42:1003-10. 2006..These findings have important implications for the continued support of HIV treatment programs in the United States...
Antibody neutralization and escape by HIV-1Xiping Wei
Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
Nature 422:307-12. 2003..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settingsRay Y Chen
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
J Acquir Immune Defic Syndr 44:525-30. 2007..We developed a more effective method based on a decision tree algorithm to classify subjects...
Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene inductionFrank Wolschendorf
Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
J Virol 84:8712-20. 2010..In the absence of such a positive feedback mechanism, cellular gene expression was not sustained, suggesting that strategies modulating the NF-kappaB activity profile could be used to selectively trigger HIV-1 reactivation...
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionJesus F Salazar-Gonzalez
University of Alabama at Birmingham, Birmingham, AL 35294, USA
J Exp Med 206:1273-89. 2009..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
Antiretroviral therapy: select lessons from recent studiesMichael S Saag
The University of Alabama at Birmingham, Birmingham, AL, USA
Top HIV Med 11:164-8. 2003
Patient-perceived barriers to antiretroviral adherence: associations with raceT F Ferguson
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham UAB, 11th Avenue South, Medical Towers Suite 401, Birmingham, AL 35205 4410, USA
AIDS Care 14:607-17. 2002..Our findings support the use of theory-based behavioural interventions that address perceived barriers to adherence and other health promotion activities...
Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9)P K Crane
Department of Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA
AIDS Care 22:874-85. 2010....
Antigenic conservation and immunogenicity of the HIV coreceptor binding siteJulie M Decker
Howard Hughes Institute, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
J Exp Med 201:1407-19. 2005..Despite remarkable evolutionary diversity among primate lentiviruses, functional constraints on receptor binding create opportunities for broad humoral immune recognition, which in turn serves to constrain the viral quasispecies...
Ryan White CARE Act reauthorization: we need helpMichael S Saag
Center for AIDS Research, The University of Alabama at Birmingham, Birmingham, AL, USA
Top HIV Med 14:93-4. 2006
HIV protease inhibitor ritonavir induces lipoatrophy in male miceEric S Goetzman
Department of Genetics, University of Alabama at Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 19:1141-50. 2003..Thus, the effects of ritonavir on serum triglycerides and body composition may be due, at least in part, to an inhibition of PPAR function...
Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literatureMelissa S Dillmon
Department of Medicine, University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA
AIDS Res Hum Retroviruses 21:753-6. 2005..We propose that awareness of the increased risk for thrombosis in HIV infection is important to the understanding of disease pathophysiology and management of these patients...
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan
University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
J Acquir Immune Defic Syndr 31:257-75. 2002..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
Roundtable. Who should be providing HIV care?Jonathan S Appelbaum
AIDS Clin Care 18:21-4. 2006
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
JAMA 288:222-35. 2002..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
JAMA 292:251-65. 2004..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
Which policy to ADAP-T: waiting lists or waiting lines?Michael S Saag
Clin Infect Dis 43:1365-7. 2006
A plea for justice for jailed medical workersSunil K Ahuja
Science 314:924-5. 2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068Jeffrey M Jacobson
Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
J Infect Dis 194:623-32. 2006....
Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection?Michael S Saag
Clin Infect Dis 45:S261-5. 2007....
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapyRichard T Davey
National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
J Interferon Cytokine Res 28:89-100. 2008..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Gerd Fatkenheuer
Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
Nat Med 11:1170-2. 2005..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapyJason D Goldman
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
AIDS Res Hum Retroviruses 24:1031-5. 2008..Among patients with suspected treatment failure, a lower MPR was associated with higher rates of detectable viremia. However, the suboptimal sensitivity and specificity of MPR limit its utility as a sole predictor of virologic failure...
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, ZambiaLloyd B Mulenga
Centre for Infectious Disease Research, Zambia
AIDS 22:1821-7. 2008..To examine the association between baseline renal insufficiency and mortality among adults initiating antiretroviral therapy (ART) in an urban African setting...
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patientsJulio S G Montaner
St Paul s Hospital, University of British Columbia, Vancouver, BC, Canada
MedGenMed 8:36. 2006..Once-daily HIV treatment regimens are being used in clinical practice with the objective of improving patient acceptance and adherence...
HIV care at a crossroads: the emerging crisis in the US HIV epidemicMichael J Mugavero
MedGenMed 9:58. 2007
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)Stephen J Gange
NA-ACCORD Coordinating Center, Baltimore, MD 21287, USA
Int J Epidemiol 36:294-301. 2007
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte responseNicola A Jones
Viral Immunology Group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire RG20 7NN, England, UK
J Exp Med 200:1243-56. 2004....
Research Grants
- ADULT AIDS CLINICAL TRIALS GROUPMichael Saag; Fiscal Year: 2004....
- Alabama-Clinical Trials UnitMichael Saag; Fiscal Year: 2007..administrative component: ..
- UAB CENTER FOR AIDS RESEARCHMichael Saag; Fiscal Year: 2007..All of the major research efforts within the Center link basic and clinical/behavioral research, and together they utilize every shared facility supported by the CFAR Core grant. ..
- RECENT ADVANCES IN AIDS AND HIV RESEARCHMichael Saag; Fiscal Year: 2007..CME credit for attending physicians will be provided. ..
- Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSMichael Saag; Fiscal Year: 2007....
- ADULT AIDS CLINICAL TRIALS GROUPMichael Saag; Fiscal Year: 2007..abstract_text> ..
